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The purpose of this project was to increase adherence to the U.S. Preventive Services Task Force 
and National Comprehensive Cancer Network guidelines for breast cancer screening and genetic 
testing. Screening for breast cancer risk factors including genetic testing helps reduce the 
incidence of breast cancer. A protocol was developed based on national clinical guidelines to 
increase screening and genetic testing for breast cancer. Provider responsibilities included 
screening all patients 18 and older for risks factors of breast cancer, referring patients with a 
significant risk based on the screening for genetic testing and providing referrals for genetic 
counseling once genetic testing was complete. One hundred fifty-four (47%) of the patients 
meeting inclusion criteria were screened with 25 (19%) having a positive screen. Fourteen (56%) 
patients with a positive screen opted for genetic testing, one patient was confirmed having a 
clinically significant mutation in the BRCA1 gene. One of the fourteen patients was identified as 
having a 35% remaining lifetime breast cancer risk and one patient was identified as having a 
non-clinically significant mutated gene. Three patients were referred to genetic counseling. One 
patient followed up with a genetic counselor. Ten (25%) patients meeting genetic testing criteria 
declined testing. BRCA gene mutations are associated with breast cancer as well as ovarian, 
melanoma, pancreatic, and prostate cancers. Providers and patients need additional education on 
the benefits of genetic testing in identifying patients at risk for breast cancer. Early detection and 
implementation of preventive measures can help reduce morbidity and mortality rates. 
Keywords: breast cancer screening, genetic testing, BRCA mutation
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Genetic Screening for Breast Cancer in Primary Care Setting 
It is estimated that there will be 2,088,849 new cases of breast cancer worldwide in 2018 
with a mortality rate of 626,679 or 30% (Bray et al., 2018). Ten percent of these breast cancers 
likely resulted from hereditary causes, with more than 50% of genetic mutations occurring in the 
breast cancer gene one (BRCA1) and breast cancer gene two (BRCA2) (Bray et al., 2018). Up to 
80% of people at risk of getting breast cancer have not received genetic testing, mainly because 
they do not meet the breast screening guidelines that were established more than 20 years ago 
(Beitsch et al., 2018). The practice guidelines have neither been updated to reflect advances in 
genetic testing that can provide clinicians with more information regarding cancer risks nor have 
the practice guidelines been updated to reflect the need to screen men for breast cancer. Due to 
the high mortality rate associated with breast cancer in both women and men, an intervention 
implementing an evidence-based practice screening tool in a primary care clinic was chosen for 
this project with the expectation that it would increase the number of people being screened. 
Screening more patients would help identify those individuals who might be at high risk for 
mutations in the BRCA genes (Bray et al., 2018). Genetic testing provides confirmation of 
mutated genes that may potentially contribute to the development of cancer, allowing individuals 
with these mutations to implement preventive measures such as lifestyle changes or starting 
mammograms earlier and more frequently (Keating & Pace, 2018). On average, women living in 
the United States have a 12.4% or a 1 in 8 risk of being diagnosed with breast cancer in their 
lifetime (DeSantis, Ma, Sauer, Newman, & Jemal, 2017). Mutations in the BRCA genes that 
cause breast cancer in women have also been linked to causing breast and prostate cancer in men 
(Bray et al., 2018). A recent genomic screening in 2018 of 50,000 people showed that over 80% 
GENETIC SCREENING FOR BREAST CANCER 9 
of individuals did not know they had identifiable genetic risks (Beitsch et al., 2018). Although 
mammograms and self-breast exams have been included in recommended screening guidelines, 
these screening guidelines do not apply to men and recent studies have shown that these 
screening methods may be contraindicated to use in the screening of young women (Keating & 
Pace, 2018). Furthermore, surveys have shown that majority of primary care providers do not 
routinely screen for breast cancer using either the old or current screening guidelines (Gornick et 
al., 2018). 
Statement of the Problem  
 Breast cancer is the most common cancer diagnosed among women in the United States 
and is the second leading cause of cancer death in women (DeSantis et al., 2017). Approximately 
41,000 people passed away from breast cancer in 2017 (DeSantis et al., 2017). It is estimated that 
in 2018, there were 266,120 new cases of women diagnosed with breast cancer, along with 2,550 
new cases in men in the United States alone (American Cancer Society, 2018). These are large 
numbers that could be reduced significantly with preventive measures including performing 
early screening for genetic testing (DeSantis et al., 2017). Between 250,000 and 415,000 men 
and women are at a high risk of being diagnosed with breast cancer that is potentially 
preventable with early detection (King, Levy-Lahand, & Lahad, 2014). Data from the National 
Cancer Institute (2012) shows the 10 year frequency and probability of developing breast cancer 
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Table 1 
Age Specific Probability of Developing Breast Cancer 
Age 10 Year Risk 10 Year Probability 
20 1 in 1,567 0.1% 
30 1 in 227 0.44% 
40 1 in 68 1.47% 
50 1 in 42 2.38% 
60 1 in 28 3.56% 
70 1 in 26 3.82% 
Lifetime risk 1 in 8 12.4%  
 
 BRCA1 and BRCA2 mutations are equally common in men as in women and are 
inherited equally from their mothers and fathers (King et al., 2014). For men, the risk of being 
diagnosed with breast cancer is about 1 in 833, with an estimated 480 deaths annually (American 
Cancer Society, 2018). Although these numbers are far less dramatic than for women, the 
mortality rate is significant at a rate of approximately 58%. This may be attributed to the fact that 
there are no breast cancer screening guidelines for men, thus by the time men are diagnosed with 
breast cancer, there is a high probability of metastasis of more advanced cancers which usually 
results in a poorer prognosis (American Cancer Society, 2018). In general, the survival rates 
improve if breast cancer is detected early (American Cancer Society, 2018). Figure 1 shows 5 
year survival rates among men correlated to the diagnosed stage of cancer as noted by the 
American Cancer Society (2018). 
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        Figure 1. Male breast cancer 5-year survival rates by stage of cancer. 
Studies have shown harm from over diagnosing breast cancers related to false-positives 
from mammography (Keating & Pace, 2018). Evidence from several randomized clinical trials 
suggest that 19% of women diagnosed by mammogram screenings are considered over 
diagnosed, subjecting women to treatment without any benefit (Keating & Pace, 2018). Over the 
past 9 years, there have been many changes in the recommendations for breast cancer screenings 
(Keating & Pace, 2018). In 2009, the U.S. Preventive Services Task Force (USPSTF) recognized 
evidence of harm from mammograms such as unnecessary surgeries, medications, further 
imaging and biopsies which has resulted in revisions to the taskforce’s recommendations that 
now include biannual mammograms for women aged 40 years to 49 years (Keating & Pace, 
2018). In 2016, 80% of the 871 primary care physicians that were surveyed still recommended 
annual screenings for women starting at age 40 years, which is contrary to the USPSTF and 
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showed 132 per 100,000 women were over diagnosed for cancer that would never show clinical 
signs or symptoms in the women’s lifetime utilizing mammograms (Welch, Prorok, O’Malley, & 
Kramer, 2016). Since many studies have linked over diagnosing breast cancer with false-
positives from mammograms, the USPSTF and the ACS have recommended the use of family 
history screening tools over mammograms in young men and women (Keating & Pace, 2018).  
Gornick et al. (2018) surveyed 537 newly diagnosed breast cancer patients to determine 
their common knowledge regarding genetic testing. The results showed that patients’ overall 
knowledge of genetic testing regarding BRCA1 and BRCA2 was low (29.8%). Gornick et al. 
(2018) found that interest in genetic testing was increasing and should be discussed as an option 
for screening within the primary care clinic. A recent study pointed out the clinical importance of 
utilizing multi-gene testing within the primary care setting as well as the fact that genetic testing 
guidelines are developing rapidly resulting in multiple revisions to genetic testing guidelines 
(Beitsch et al., 2018). Furthermore, genetic testing criteria have become more complicated, yet 
these criteria have not been sufficiently re-evaluated (Beitsch et al., 2018). It is estimated that 1.2 
to 1.3 million women with a history of breast cancer have not undergone genetic testing despite 
USPSTF and the ACS’ evidence-based practice guidelines supporting this type of testing as a 
standard of care (Childers, Childers, Maggard-Gibbons, & Macinko et al., 2017). Furthermore, 
over 70% of eligible patients with breast cancer have never discussed genetic testing with a 
health care provider (Childers et al., 2017). There is increasing evidence, which supports the 
benefits of identifying BRCA gene mutations in early breast cancer to evaluate the risk of 
recurrence (Nilsson et al., 2017). 
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Assessment 
The clinic where the evidenced based practice project was implemented is located in the 
northeast side of San Antonio, Texas. The clinic is privately owned and staffed with one 
physician, one nurse practitioner, an office manager, two administrative personnel, and three 
medical assistants (MA) that are bilingual in English and Spanish. Each provider typically sees 
about 15 to 20 patients a day, with the majority of patients being private insurance holders. 
Figure 2 provides a summary of the ethnic groups seen in the clinic and figure 3 provides a 
summary of the age groups seen in the clinic. As shown, the clinic sees primarily Caucasian 
patients between the ages of 45-64 years.  




Caucasian Hispanic African American Other
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Figure 3. Age groups of the patient population within the clinic. 
This clinic did not screen for breast cancer, nor did they offer genetic testing prior to this 
project intervention. During the microsystem assessment 100 patient charts were audited, which 
revealed that 42% of the patients met the national recommended guidelines to be offered genetic 
testing. Many organizations defer to the USPSTF guidelines, because this group of health experts 
review the strength of the evidence found in the research and determine the benefits and harms 
each reviewed method poses to patients (USPSTF, 2018a). The USPSTF makes 
recommendations based off their reviews of the evidence to help guide healthcare providers in 
managing their patients appropriately. The USPSTF national guidelines for genetic testing 
recommend that patients who have had one family member diagnosed with either breast, colon, 
or uterine cancer under the age of 49 years be considered to have an increased risk for potentially 
harmful mutations in BRCA1 and BRCA2 (Hampel, Bennett, Buchanan, Pearlman, & Wiesner, 
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age, then they too should be considered a high risk for BRCA 1 and BRCA 2 mutations and 
should be offered genetic testing (Hampel et al., 2015). 
Organization’s Readiness for Change 
 Upon review of the USPSTF guidelines and the results of the microsystem assessment it 
was determined in consultation with the key stakeholders that the clinic was not aligned with the 
current national guidelines. Both providers had personal experiences with cancer affecting family 
members thus they were interested in learning more regarding genetic screening and testing. 
Both providers were already aware that genetic testing for cancer existed, however they were 
unaware of the practice guidelines that determine which patients should be screened. This 
interest in practice guidelines for genetic screening and testing is what made the key stakeholders 
ready to implement my project. They had expressed an interest in offering genetic screening and 
testing to their patients and were aware that they needed education on the national practice 
guidelines for screening. 
After identifying that a problem existed in the clinic, I developed a project to implement a 
process that would screen, test, and provide referrals to patients at high risk for BRCA mutations 
based on the USPSTF guidelines. A short meeting was held with the office manager and each 
provider individually to fully explain the project’s intent and to create a protocol that involved all 
of the stakeholders. The staff and providers were able to verbalize an understanding of the 
project’s purpose, objectives and interventions. The providers and staff expressed a willingness 
to participate in this project implementing the evidence-based USPSTF guidelines for BRCA 
testing in the clinic as a method of improving patient care for both women and men in this 
patient population. 
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Project Identification 
Purpose and Objectives 
 The purpose of this project was to implement an evidence-based practiced screening 
process that included genetic counseling and genetic testing for patients who were considered at 
high risk for breast cancer in order to improve patient outcomes according to the USPSTF 
guidelines. The USPSTF guidelines recommend screening all patients, both men and women, 
and when appropriate, provide genetic testing and referral for genetic counseling to ascertain 
genetic risks for gene mutations associated with breast cancer. 
 The objectives for this evidence-based practice project were to: 
1. Increase patient screenings for risk factors associated with breast cancer from the pre-
intervention rate of 0% to 80% by the completion of the 5th week of the project. 
2. Increase the percentage of genetic testing from 0% to 80% in those patients identified 
as high risk based on screening. 
3. Increase the percentage of referrals for patients with genetic mutations to genetic 
counseling from the pre-intervention rate of 0% to 95%. 
Anticipated Outcomes 
Prior to the start of my project it was anticipated that implementation of the screening 
tool would result in the clinic experiencing an increased number of patients being identified as 
high risk for breast cancer, thus possibly leading to genetic testing and subsequent genetic 
counseling. Since I anticipated that the clinic would experience an increase in genetic screenings, 
genetic testing, and genetic counseling referrals, I also predicted that the providers would be 
willing to continue the implemented interventions, increasing the likelihood that the project 
would be sustainable.  
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Summary and Strength of Evidence 
 Melnyk and Fineout-Overholt’s (2015) system of grading the quality and level of 
evidence was used for this project. The quality of the evidence was rated using a I-IV scale and 
the level of evidence was rated using a I-VII scale. Specifics regarding the criteria that Melnyk 
and Fineout-Overholt (2015) define for the numerical rating scales can be found in table 2 and 
table 3, respectively. 
Table 2 
Quality of Evidence 
Quality of Evidence Criteria 
I Acceptable quality: No concerns 
II Limitations in quality: Minor flaw or inconsistencies 
in the evidence 
III Major limitations in quality: Many flaws and 
inconsistencies in the evidence 
IV Not acceptable: Major flaws in the evidence 
 
Evidence relevant to this project was identified with a comprehensive literature search. 
Searches were performed using PubMed and CINAHL. In addition, the Cochrane Library and 
the National Guideline Clearinghouse databases were searched. Searches were conducted using 
the key words BRCA, genetic testing, mammograms, breast cancer and cancer genes. The 
reference lists in the selected articles were also reviewed for pertinent evidence. Research articles 
from the primary care settings, oncology settings, as well as position statements and guidelines 
from professional associations and societies were also reviewed. Based on this literature review 
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15 articles were reviewed and rated. 
Table 3 
Level of Evidence 
Level of Evidence Study Design 
I Systematic reviews and meta-analysis of randomized controlled studies 
II Randomized controlled studies 
III Non-randomized controlled studies (quasi-experimental) 
IV Case-control or cohort studies 
V Systematic reviews of qualitative or descriptive studies 
VI Qualitative or descriptive studies 
VII Opinion of authorities and/or reports of expert committees 
 
Intensive screening for breast cancer is associated with an increase in false-positive 
results, unnecessary imaging, and unneeded surgery (USPSTF, 2018b). Other studies have 
confirmed that mammograms can result in higher rates of false-positives (King et al., 2014). 
False positive results lead to prescribing medications such as tamoxifen and raloxefine which 
increases the risk in women for thromboembolic events, cataracts and endometrial cancer (King 
et al., 2014). Additionally, women identified as being at high risk for breast cancer by 
mammograms have had unneeded surgeries resulting in complications such as hematomas, 
contractures, numbness, pain, infection, swelling, bleeding, pulmonary embolisms, and 
decreased sexual function due to changes in the body (USPSTF, 2018b). 
Henderson, Hubbard, Sprague, Zhu, & Kerlikowske (2015) conducted a study that 
showed women who had false-positive mammogram results that led to additional imaging and 
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testing were at a higher risk of having breast cancer within the next decade. During the 10 year 
follow-up of 12,022,560 people, 48,735 cancers were diagnosed (Henderson et al., 2015). When 
compared to women with a true-negative examination, women with a false-positive with 
additional imaging recommendation had increased risk of developing breast cancer as did 
women with a false-positive with a biopsy recommendation (Henderson et al., 2015). Women 
with a false-positive result had persistently increased risk of developing breast cancer 10 years 
after the false-positive examination (Henderson et al., 2015). There is no definitive explanation 
regarding why false-positive mammograms appear to be linked to a slightly higher risk of 
invasive disease but it was hypothesized that the breast tissue changes that lead to the false-
positive mammogram result might in fact be predictive of future breast tissue changes 
(Henderson et al., 2015). Many studies have concluded that subtle changes on mammograms 
may be an early clue to cancer before actual cancer exists (Puliti et al., 2012). It is also important 
to note that these finding has been seen in multiple studies. Studies with large sample sizes of 
women and extended lengths of follow-up have contributed to more evidence linking false-
positive results with a higher risk of invasive breast cancer later in life (Puliti et al., 2012). 
Approximately 67% of women 40 years of age and older have had a mammogram screening 
biannually with 16% of the first mammogram and 10% of subsequent mammograms resulting in 
false-positives (Henderson et al., 2015). Over a period of 10 years, the probability of having at 
least one false-positive mammogram is 61% for women who were screened annually and 42% 
for women who were screened biannually (Henderson et al., 2015).  
These results are consistent with several studies, such as the study by Euler-Chelpin, 
Risor, Thorsted, and Vejborg (2012) that found a 67% increased risk for breast cancer among 
women with false-positives. Another study that was conducted over the course of 17 years found 
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that false-positives from mammograms involving fine needle aspiration cytology or biopsy had a 
significantly higher risk for breast cancer than women who had additional imaging procedures 
alone (Castells et al., 2013). In this study, the overall cancer detection rate was 2.89 cases for 
every 1,000 mammogram screenings (Castells et al., 2013). The detection rate for women with a 
history of a false-positive result involving additional imaging was 4.53 per 1,000 mammogram 
screenings, and those involving a fine-needle aspiration were 7.09 per 1,000 screenings (Castells 
et al., 2013). The study identified other factors associated with higher detection rates including 
having a first-degree family history of breast cancer (Castells et al., 2013). Additionally, a study 
conducted in the United Kingdom, found that women who had a false-positive result from their 
first mammogram, had a higher interval cancer rate than women with true negatives and also had 
more advanced stages of cancer (McCann, Stockton, & Godward, 2002). However, as previously 
mentioned, there is insufficient evidence to determine the association between false-positives and 
high risks of developing cancer. This study concluded that false-positive mammographies 
leading to unnecessary assessment of cancer free women has unintended associated costs 
(McCann et al., 2002). First, there are psychological costs associated with the inconvenience of 
the procedure and increased anxiety in women that were falsely identified (McCann et al., 2002). 
Second, there are the direct financial costs associated with performing the procedures (McCann 
et al., 2002). 
In a nonrandomized comparison study by Riedl et al. (2015), BRCA mutation carriers 
and women with a high familial risk for breast cancer were offered triple and single diagnostic 
screenings with mammography, ultrasound, and magnetic resonance imaging (MRI) every 12 
months. Diagnostic performance was compared between individual modalities and their 
combinations. Additional comparisons included age, mutation status and breast density. There 
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were 559 women with 1,365 completed imaging rounds included in this study (Riedl et al., 
2015). The sensitivity of MRI (90.0%) was significantly higher than that of mammography 
(37.5%) and ultrasound (37.5%) (Riedl et al., 2015). Out of 40 cancer types, 18 were detected by 
MRI alone and two cancers were found by mammography alone (Riedl et al., 2015). The triple 
modality approach, which included all three diagnostics, yielded the highest detection rate, but 
also had higher false-positives and costs (Riedl et al., 2015). Age, mutation status, and breast 
density had no influence on the sensitivity of MRI and did not affect the superiority of MRI over 
mammography and ultrasound (Riedl et al., 2015). 
Current evidence suggests that genetic testing can accurately detect BRCA mutations 
with little to no risk of harm associated with testing in both men and women (USPSTF, 2018). 
However, consideration of screening for BRCA mutations should begin once the individual 
reaches 18, the age of consent (King et al., 2014). In 1995, the American Society of Human 
Genetics (ASHG) and American College of Medical Genetics and Genomics (ACMG) issued a 
joint report that offered points to consider for genetic testing in children. The clinical context of 
that report focused on decisions about testing for single-gene disorders in response to either a 
family history or within-population screening programs (Botkin et al., 2015). The social context 
of that report included limited data about the psychosocial impact of such testing in children. The 
ASHG and ACMG recommended that clinicians and parents consider medical benefits related to 
diagnosis, prognosis, and interventions as the best justification for testing in children (Botkin et 
al., 2015). Additionally, the report acknowledged that there was limited information about risks 
and benefits of genetic testing in children thus the report recommended deferral of testing due to 
this uncertainty. The report has been influential in encouraging caution when testing children, 
but often has been over-interpreted as a stricter prohibition of predictive testing in children for 
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adult-onset conditions than was intended (Botkin et al., 2015). There has been a significant 
increase in research regarding the impact of predictive testing in high-risk families since the first 
ASHG ACMG pediatric testing statement, which was established over 20 years ago (Botkin et 
al., 2015). To date, this limited research has not found evidence of significant psychosocial 
harms in children (Botkin et al., 2015). Currently, the ASHG now offers the following 
recommendations: 
• Unless there is a clinical intervention appropriate in childhood, parents should be 
encouraged to defer predictive or pre-dispositional testing for adult-onset conditions until 
adulthood or at least until the child is an older adolescent who can participate in decision 
making in a relatively mature manner (Botkin et al., 2015). 
• Adolescents should be encouraged to defer predictive or pre-dispositional testing for 
adult-onset conditions until adulthood, because of the complexity of the potential impact 
of the information at formative life stages (Botkin et al., 2015). 
• Providers should offer to explore the reasons why parents or adolescents are interested in 
predictive or pre-dispositional testing for adult-onset conditions. Providers can 
acknowledge that, in some cases, testing might be a reasonable decision, but decisions 
should follow a thorough deliberation (Botkin et al., 2015). 
More than 90% of hereditary cases of breast cancer are thought to be a result of a 
mutation in BRCA1 and BRCA2 (Paluch-Simon et al., 2016). A founder mutation or founder 
variant is a genetic alteration observed in high frequency within a group, in which one or more of 
the ancestors was a carrier of the altered gene (National Cancer Institute [NIH], 2018). Over 
2,000 different mutations have been identified in BRCA1 and BRCA 2 genes with founder 
mutations being the most prevalent in some populations (Paluch-Simon et al., 2016). For 
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example, up to 2.5% of the general Ashkenazi Jewish population harbor a mutation in either the 
BRCA1 (C.5266dupC) or BRCA2 (c.5946delT) (Paluch-Simon et al., 2016). 
A recent study with a rather large sample consisting of 8,000 men studied the association 
between relatives who were carriers of BRCA gene mutations. All participants were healthy, 
cancer-free men that were tested for genetic BRCA1 and BRCA2 mutations. Out of the 8,000 
men, 175 tested positive for having BRCA1 or BRCA2 genetic mutations (King et al., 2014). 
Female relatives of the 175 men were then tested for the same gene disorders and were found to 
be carriers of the same BRCA mutations, placing them at a very high risk for cancer (King et al., 
2014). The evidence supports offering genetic testing to those with personal or family history of 
cancer, and to those who are relatives of confirmed carriers (King et al., 2014). 
The reviewed evidence consistently agreed that genetic testing is still rather new and as 
newer, more advanced equipment is developed, more research is still needed. With that being 
said, much of the level I evidence recommends reviewing and revising the current genetic testing 
guidelines to reflect current evidence and recent trials. Several of the level I studies support the 
recommendations that mammograms should not be the sole basis of screening men and women 
for breast cancer. The evidence suggests that there is a benefit of BRCA genotyping patients who 
are newly diagnosed with breast cancer and recommends genetically testing men and women for 
mutations that suggest an increase likelihood of developing cancer allowing for early 
implementation of preventive measures. 
Nelson et al. (2013) reviewed 70 studies evaluating the evidence on the benefits and 
harms of risks assessments, genetic counseling and genetic testing. Results showed those who 
received counseling post genetic testing experienced less depression and worry regarding both 
low and high-risk genetic results (Nelson et al., 2013). Although evidence such as this suggesting 
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that offering genetic counseling with genetic testing reduces depression and anxiety, recent 
studies have shown that providers are not adhering to these recommendations (Armstrong et al., 
2015). A study by Armstrong et al. (2015) identified factors associated with use of BRCA testing 
to assess whether delivery of genetic counseling and testing services was adhered to as part of 
the professional guidelines and measures the impact on patient-reported outcomes. This study 
analyzed data from providers throughout the United States and collected data from 11,159 
women whose provider ordered BRCA testing between December 2011 and December 2012. 
Findings revealed that only 1,334 (36.8%) women received genetic counseling prior to genetic 
testing with the lowest rates 130 (12.3%) among patients of obstetricians and gynecologists 
(Armstrong et al., 2015). The most commonly reported patient reason for not receiving 
counseling was due to lack of provider recommendation (Armstrong et al., 2015). This study also 
concluded that the patients that did receive genetic counseling demonstrated greater knowledge 
about BRCA mutations, greater understanding of the genetic information, and expressed greater 
satisfaction (Armstrong et al., 2015). 
During the review of the evidence, it is apparent that there is very little research 
concerning breast cancer in men. It is under acknowledged clinically and socially as a real risk to 
men’s health, even though breast cancer in men persists as a critical health issue with complex 
ramifications for those affected (Sirieix et al., 2018). Breast cancer in men accounts for 1% of all 
breast cancer and management is still largely based on breast cancer management in women 
(Sirieix et al., 2018). Only a small amount of retrospective series on metastatic cases have been 
reported so far (Sirieix et al., 2018). Currently there is a multi-center project that aims to collect 
data from clinical trials and comprehensive cancer centers to improve the customized 
management of breast cancer in men. So far, the only conclusive finding is that compared to 
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women, the prognosis and treatment effects for male breast cancer are the same (Sirieix et al., 
2018). Unfortunately, studies examining male breast cancer are not routinely funded (Sirieix et 
al., 2018). Recently the National Comprehensive Cancer Network (NCCN) (2019) started 
recommending that men age 35 years or older start performing self-breast exams and have an 
annual breast exam performed by providers. It is evident, that more research is needed to be able 
to offer early preventive measure to both men and women and if necessary, early interventions to 
reduce morbidity and mortality rates for these patients. 
Methods 
Project Intervention 
Prior to implementation of this project several meetings were held with the clinic 
providers and staff based on their roles in implementing the project. A demonstrational meeting 
was held for the front desk personnel and MAs to allow them to visualize the workflow of the 
intervention and to ask questions about the implementation process. Another meeting was held 
on the same day with the laboratory technician to verify that she understood all of the 
components in the genetic testing kit that needed to be completed in order to process patient 
samples. The laboratory kit contained one lavender tube and a consent form (see appendix B). 
The laboratory technician completed a successful return demonstration of how to process the 
genetic kits. The laboratory technician was familiar with the genetic kit as she had previously 
processed some samples the previous year. A final meeting was held with both providers to 
explain the workflow of the intervention and to identify possible barriers to implementation. 
Starting on day 1 of implementation, each patient 18 years of age and older entering the 
clinic was given an electronic tablet issued by the clinic’s genetic lab company of choice, Myriad 
Genetics, which contained an electronic hereditary cancer risk survey. Myriad Genetics was the 
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clinic’s preference because this company currently offered a 35-gene panel (see appendix C) that 
tests for nine types of cancers and 11 genes (see appendix D) that are not only specific to breast 
cancer, but also to ovarian cancer, melanoma, pancreatic cancer and prostate cancer. This was 
important for the clinic because the results of a recent study showed that those identified with 
BRCA1 mutations had a higher incidence of breast cancer, ovarian cancer and melanoma 
(Mersch et al., 2015). This same study showed that BRCA2 mutations were reported to increase 
the risk of developing pancreatic cancer and prostate cancer (Mersch et al., 2015). The electronic 
tablets containing the online screening survey were handed to the patients during check in by the 
front desk receptionist and patients were asked to complete the screening survey. Once the 
electronic tablet screening survey was completed, the tablet was handed back to the front desk 
receptionist. The electronic tablet screening survey, MyRisk Screening Survey, is an online 
screening tool by Myriad Genetics that utilizes the USPSTF and the NCCN national clinical 
guidelines for screening tools in genetic testing. The MyRisk Screening Survey incorporates the 
national clinical guideline which state if the patient has one family member diagnosed with either 
breast cancer, colon cancer, or uterine cancer under the age of 49 years, then they should be 
deemed as having an increased risk for potentially harmful mutations in breast cancer 
susceptibility genes (Hampel, Bennett, Buchanan, Pearlman, & Wiesner, 2015). Another 
consider is if a family member has had ovarian cancer or pancreatic cancer at any age, then they 
too should be deemed as having an increased risk for mutations in the BRCA1 and BRCA2 
genes (Hampel et al., 2015). All patients meeting any of these criteria should be offered genetic 
testing to be in compliance with current national clinical guidelines. 
Once the electronic screening survey was completed, a risk score was generated 
recommending either performing genetic testing (see appendix E) or not performing genetic 
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testing (see appendix F). The receptionist would then print out and attach the risk score report to 
the patient’s chart, and the MAs would place the entire chart outside the patient’s room for the 
providers as per their usual protocols. The only difference was the charts now contained the 
patients’ risk score reports. The providers reviewed the risk score reports and explained 
recommendations for genetic testing along with the pros and cons of genetic testing. The 
providers were educated about the USPSTF national guidelines recommending offering genetic 
counseling prior to testing, but both providers declined this part of the intervention. The 
providers stated that insurance companies would not pay for genetic counseling prior to genetic 
testing. Instead, the providers performed basic genetic counseling themselves to educate the 
patients about genetic testing discussing the fact that genetic testing does not detect cancer, but 
rather determines the genetic risk of developing cancer based on any mutations in genes. If 
patients were screened as high risk, the providers would encourage genetic testing to be 
performed. If a patient agreed to genetic testing, the providers would review the consent form 
supplied in the testing kits with the patient and a signature was obtained consenting to the 
testing.  
  Once the consent form was signed, the provider would walk the patient to the in-house 
laboratory to have their blood drawn by the laboratory technician using a lavender tube. The 
laboratory technician would then place the specimen in a pre-posted package setting it aside for 
pick up by FedEx. Once the genetic company received the specimen, the company would contact 
the patient’s insurance and determine if the genetic testing would be covered. All genetic testing 
was reported as being covered so no missed opportunities occurred for this reason. The average 
turn-around time to receive results was approximately 10 to 14 business days. Each provider 
would receive a notification via email informing them that results had been uploaded into the 
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database and were ready for viewing. Results indicated the inherited genetic risk of developing 
cancer. Based on the presence of mutated genes, a report was generated that provided a 
percentage risk of developing breast cancer within 5 years and a percentage risk of developing 
cancer over one’s lifetime (see appendix G). For example, results associated with a high-risk 
patient may state that the patient has a 38% chance of developing breast cancer within 5 years 
and a 60% chance of developing breast cancer over the course of the patient’s lifetime. Results 
could also indicate that a patient was at low risk for developing breast cancer if no signs of 
genetic mutations existed for any of the breast cancer genes (see appendix H), in which case the 
provider would inform the patients of the results over the telephone. Patient’s that had genetic 
mutations were scheduled by the front desk receptionists to be seen in the clinic to discuss the 
results and were then educated by the provider on preventive measures and lifestyle 
modifications such as quitting smoking, exercising regularly, and increasing foods associated 
with higher levels of antioxidants to reduce their chances of developing breast cancer (American 
Cancer Society, 2018). The providers also educated the patients about additional and alternative 
screening measures. These recommendations included those listed by the USPSTF (2018b) for 
BRCA mutation carriers to reduce risk for cancer or cancer related deaths such as intensive 
cancer screening, risk reducing medications, and risk reducing surgeries. Medications such as 
tamoxifen and raloxifene have been shown to reduce the incidence of invasive breast cancer in 
high risk women, but have not been studied in men (USPSTF, 2018b). The patients were also 
educated that risk reducing surgeries such as mastectomy and salpingooophorectomy 
significantly reduce the risk of developing breast cancer (USPSTF, 2018b). The USPSTF 
(2018b) also recommends women who have been genetically identified as being high risk for 
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developing breast cancer to start receiving mammograms twice annually and if currently only 
receiving mammograms annually, then switching to screening twice a year. 
After the primary care providers discussed the results and recommendations with the 
patient, the providers offered a referral to one of the local genetic counselors based on the 
patient’s insurance coverage. A referral to a geneticist counselor was recommended to reduce the 
incidence of the patient developing anxiety or depression due to having received results (Nelson 
et al., 2013). If the patient agreed to attend genetic counseling, the receptionist would submit the 
referral. The patients who had declined a genetic counseling referral only received the basic 
recommendations from the provider that was previously mentioned. There were no incidences 
where the insurance did not cover the genetic counseling and there were no patients who 
declined a referral based on their personal insurance coverage. 
Organization Barriers and Facilitators  
 Barriers. The organization experienced a few barriers to implementing the interventions 
as planned. These barriers included failure to screen all patients 18 years and older, loss of wi-fi 
connectivity and software updates required with the electronic tablets, patients not understanding 
how to use the tablets as well as patients not willing to participate after receiving the patient 
education. 
 Initially the front desk receptionists kept forgetting to hand out an electronic tablet to 
each patient who was 18 years of age and older. However, after another meeting with the front 
desk receptionists to re-educate the importance of the screenings, they were more consistent with 
screening every eligible patient by week 2. 
At times the electronic tablets would have some connectivity issues, or the electronic 
tablet software needed to be updated. The front office receptionists attempted to reset the 
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electronic tablets to correct these issues, but if this intervention did not correct the problem, no 
other attempts were made. These electronic tablets were not available to use until I fixed the 
issues, which resulted in multiple missed opportunities between week 1 and week 3. 
The most significant barrier occurred with elderly patients who did not know how to use 
the electronic tablet or did not understand the survey questions. This required the front desk 
receptionists to assist these patients in completing the survey as they were the first person 
available to the patients. During the pre-intervention stage of the project, the receptionists were 
asked to complete the survey so they would have a good understanding of how it worked, what 
to expect and how to answer certain screening questions should the patients have any questions. 
The front office receptionists successfully assisted each patient that required assistance, thus no 
missed opportunities were attributed to this barrier. 
However, there were many misconceptions among the patients regarding the screening 
and the testing that may have altered their decision to participate in the project. Some common 
misconceptions verbalized by the patients included:  
• “I don’t have any kids, so it doesn’t matter.” 
• “There is nothing I can do if I have the mutated gene.” 
• “I get mammograms, so I don’t need to get tested.” 
• “I probably wouldn’t have to worry either way since I’m a male.” 
• “I’m too old to have to worry about genetic testing for breast cancer.” 
Facilitators. Facilitators to implementing the project interventions included staff 
familiarity with BRCA genetic testing, the clinic’s affiliation with a genetic laboratory company, 
patients’ willingness to participate in the project, and staff familiarity with processing the 
laboratory kits and consent forms.  
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The clinic’s nurse practitioner was familiar with the genetic testing process since she had 
previously processed a few patients for genetic testing in 2017. However, these patients were not 
screened or tested accordingly to any guideline and were only tested due to the patient’s own 
concerns of having breast cancer. Both providers were already familiar with the genetic 
laboratory company’s processes and already had the lab kits needed for blood draws in storage.  
The laboratory technician was also familiar with obtaining the specimens since she was the one 
who performed the testing in 2017. The clinic had a previous affiliation with the genetic 
laboratory company used for this project because this company processed the genetic tests in 
2017. As a result of already having an affiliation in place, the genetic company provided the 
electronic tablets and laboratory kits to the clinic at no cost. 
Patients were also facilitators to this project, as the majority of eligible patients were 
interested in completing the electronic tablet screening survey. Some of the reasons that patients 
participated in the project were patients possessing personal knowledge about genetic testing, 
curiosity and interest about genetic testing, personal predispositions that motivated patients to 
have genetic testing done, and some patients having friends or family that received genetic 
testing and recommended the screening to the patient. 
Ethical Considerations 
 As with any project, it is important to consider ethical considerations. When researching 
similar studies, no one reported patients experiencing any harm from participating in a cancer 
risk assessment (Moyer, 2014). However, as previously mentioned prior studies have shown an 
increased in anxiety and depression after meeting criteria for genetic testing or after receiving 
results. By the same token, other studies have reported a decrease in anxiety, depression, worry 
and an increase in the accuracy of risk perception after counseling (Moyer, 2014). After 
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disclosing this information to the providers, an agreement was reached that the providers would 
provide the initial genetic education themselves because they felt that an initial genetic 
counseling session would not be covered by insurance prior to testing. However, both providers 
agreed that a post genetic testing referral would be implemented into the project interventions. 
 According to the American College of Obstetricians and Gynecologists (ACOG) (2014), 
another ethical dilemma that should be considered is having a formal consent, which explains 
that genetic testing may have important consequences or require difficult choices. For example, 
patients should be informed that the test might reveal that they have, are at risk for, or are a 
carrier of a specific disease (ACOG, 2014). The results of genetic testing may require difficult 
decisions to be made regarding current or future health choices, insurance coverage, career, 
marriage, or reproductive options (ACOG, 2014). The providers provided a consent form to 
every patient who agreed to genetic testing. The consent form included information regarding the 
purpose of testing, the testing procedure, as well as the risks, benefits and limitations of genetic 
testing. Also included in the consent form was a description about how test result findings are 
reported and what these descriptions mean. The descriptions were defined as: 
• Positive: A mutation that is associated with an increased risk for hereditary cancer was 
identified. 
• Negative: A mutation was not identified in any of the genes included as a part of your 
testing. 
• Uncertain: A genetic change was detected but it is not known if this change is linked to 
cancer risk.  
The full consent form can be found in appendix B. 
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A provider ethical dilemma is the inability of the providers to warn the at-risk relatives of 
the genetic mutations. Genetic testing is absolutely confidential. Although the provider may 
inform the patient of familial implications for at-risk relatives, confidentiality and federal laws 
restrict providers from disclosing any genetic information to relatives without consent of the 
patient (Knoppers et al., 1998). It is important that consents for genetic testing provide a warning 
to patients that they may be faced with this dilemma and they should consider having genetic 
counseling prior to testing (ACOG, 2014). 
This project was referred to the University of The Incarnate Word Institutional Review 
Board (IRB) for review and was deemed not regulated research. Authorization (NRR [19-037]) 
was given to proceed with the project since it did not require IRB approval. 
Results 
This project lasted 5 weeks, with 154 of 329 eligible patients being approached for 
screening using the electronic screening survey. Out of the 154 eligible patients that were asked 
to complete the electronic screening survey, 129 (40%) of them completed it. Twenty-five (19%) 
of the 129 patients screened had positive screens that resulted in a recommendation for genetic 
testing based on their family and personal history. Fourteen (56%) of the 25 patients chose to 
have genetic testing done. Figure 4 shows the patients who had positive high risks screens 
recommending genetic testing per each week and Figure 5 shows the patients that proceeded 
with genetic testing each week. 
Three women (21.4%) who consented for genetic testing were identified as having a high 
risk of developing breast cancer. One female patient was identified as having a clinically 
significant mutation in the BRCA1 gene. This patient had an estimated 46% - 87% risk of getting 
breast cancer by the age of 70 years, whereas the general population for her age group only had a 
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      Figure 4. High risk screens. 
       Figure 5. Patients who received genetic testing. 
7% risk. The second female patient was identified as having a 35% remaining lifetime risk based 
on her family history. The third female patient was found to have had a mutated gene, with 
uncertain clinical significance due to insufficient data to determine if the variant was linked to an 
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follow up with the patient if and when new research studies identify any new additional 
information regarding the uncertain mutations. 
 Since the implementation of the project, all three (100%) patients with confirmed high 
risks have been referred to genetic counseling. As of to date, one followed up with the genetics 
counselor to review her results.  
 The number of genetic testing opportunities offered by each provider varied significantly. 
Provider one explained that she had a family history of cancer and felt it was important to offer 
this service to all patients. Provider two also expressed the importance of genetic testing, but he 
did not want to make the patients feel pressured into getting genetic testing. Table 4 shows the 
overall weekly screening rates for the clinic whereas table 5 shows the weekly testing rates by 
each provider. Table 6 shows the comparison between the pre-intervention rates for each project 
objective and the post-intervention rates for each project objective. 
 
Table 4 
Weekly Screening Rate 
 Screenings Denied Screenings 
Week 1 19 8 
Week 2 15 3 
Week 3 7 10 
Week 4 24 3 
Week 5 64 1 
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Table 5 
Weekly Genetic Testing Rate by Provider 
 Provider 1 Provider 2 
Week 1 4 0 
Week 2 2 1 
Week 3 0 0 
Week 4 3 0 
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Objective     
Met 
Patient Screening 
80% 0% 40% Not met 
Genetic Testing 
80% 0% 56% Not met 
Genetic Counseling 
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Discussion 
The electronic hereditary cancer risk survey was not given consistently to patients for the 
first four weeks of implementation. Due to some of the barriers mentioned such as losing wi-fi 
connectivity, electronic tablets in need of software updates, and patients’ lack of willingness to 
participate, the clinic was unable to maximize the number of patients screened. On several 
occasions, I would sit with the front desk receptionists to review the project and interventions 
clarifying any questions they had. During these times I would also review functionality of the 
electronic tablets to teach the front desk receptionists how to fix some basic errors such as 
resetting the wi-fi, restarting the tablet and downloading software. By frequently visiting with the 
front desk receptionists, they became more familiar with the project, and operating the electronic 
tablets as well as learning the impact the project has for the clinic’s patients. This resulted in 
more efficiency and consistency in the last two weeks of the project.  
 Analysis of the data revealed no significant similarities among the three women who 
were found to have genetic mutations of BRCA1 or BRCA2. Table 7 highlights patient 
demographics and reproductive history of the three women who tested positive for genetic 
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Table 7 
Comparison of Patients Identified with BRCA Gene Mutations 




13 21 No Caucasian 
Patient 2 
12 25 Yes Hispanic 
Patient 3 
15 21 No Caucasian 
 
These results differ from larger sample size studies that revealed that BRCA mutation 
prevalence differed in women diagnosed with breast cancer based on ethnicity and race (Greenup 
et al., 2013). Figure 6 shows the BRCA mutation prevalence rates by ethnicity as identified by 
Greenup et al. (2013). This differs from findings from this project, which revealed a more 
homogenous distribution of patients who had a higher risk of breast cancer based on the 
electronic screening. Table 7 shows the ethnicity of the 14 women who had genetic testing done 
based on the initial screening in the clinic. The difference in distribution may be attributed to the 
fact the primary ethnicity of this clinic’s patient population was Caucasian. 
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Figure 6. BRCA mutation prevalence by ethnicity. 
In the study by King et al. (2014), the evidence supports offering genetic testing to those with 
personal or family history of cancer and to those who are relatives of confirmed carriers. Results 
from this project revealed three out of 14 (21%) patients with a family history of cancer had an 
increased risk for developing breast cancer. King et al. (2014), found that the combined risk of 
developing either breast or ovarian cancer was 60% (±7%) by age 60 years and 83% (±7%) by 
age 80 years in BRCA1 mutation carriers. For BRCA2 mutation carriers the risk was 33% (±9%) 
by age 60 years and 76% (±13%) by age 80 years (King et al., 2014). All three women in this 
project identified as having a high risk for developing breast cancer were 50 years of age or 
older. The one patient that had a BRCA1 significant gene mutation was 65 years of age. The two 
patients who had a high risk for developing breast cancer that were in their 50’s differ from King 
et al.’s (2014) findings whereas the one 65-year-old patient with the BRCA 1 significant gene 
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Figure 7. Clinic ethnicity of women complete genetic testing. 
The summary of evidence provided plenty of evidence that genetic counseling is a benefit 
to patients who are receiving genetic counseling as it decreases anxiety and depression and 
increases understanding of genetic testing results. Unfortunately, the evidence also revealed that 
providers are not routinely adhering to this recommendation (Armstrong et al., 2015). This was 
similar to findings from this project, as both providers declined offering genetic counseling prior 
to genetic testing based on patient cost concerns. They did however adhere to the USPSTF’s 
(2018a) recommendations of referring patients to a geneticist counselor following genetic 
testing. Armstrong et al. (2015) identified that out of the 11,159 patients who received genetic 
testing, only 1,334 (36.8%) women received genetic counseling prior to genetic testing. 
Interestingly enough, this project found that one of the reasons for the lack of pre-genetic testing 
referrals was due to lack of provider recommendations which is consistent with findings by 
Armstrong et al. (2015). 
33.3%20%
Caucasian Hispanic
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A study conducted by Struewing et al. (1997) found that the NCCN guidelines at the time 
regarding genetic testing under identified patients with BRCA1/BRCA2 genetic mutations. The 
study randomly selected 1,000 volunteers who had completed a family history survey and 
provided a blood sample with permission to analyze it for mutations in the BRCA1 and BRCA2 
genes. Out of the 1,000 men and women tested, 120 participants were found to have BRCA gene 
mutations (Struewing et al., 1997). Of the 120 participants who carried a BRCA gene mutation, 
31 did not report a family history of breast or ovarian cancer among first- or second-degree 
relatives (Struewing et al., 1997). This led to a recommendation to revise guidelines for breast 
cancer screening to include additional familial history such as the ones used for this project’s 
interventions. It is interesting to note that few changes have been made to the genetic screening 
recommendations from the NCCN over the past 20 years. When comparing this project’s results 
with other studies such as Struewing et al. (1997) and Beitsch et al. (2018), the similarities in 
results are interesting. Table 8 provides a side-by-side comparison of this project’s results with 
these two studies. 
 
Table 8 
Results Comparison of Patients Identified with Having BRCA Gene Mutations 
Studies Sample Size Results 
This project 14 7% 
Struewing et al. (1997) 1000 12% 
Beitsch et al. (2018) 959 9% 
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 Factors that may have influenced the findings from this project that prevent any 
assumptions being made about these similarities include the small size of this project’s 
population as well as the homogeneity of the clinic’s population and the type of insurance of the 
clinic patients. No men agreed to participate in genetic screening for this project. Therefore it is 
difficult to know whether any correlation exists between personal and family history of cancer 
and genetic mutations in the BRCA1/BRCA2 genes. Furthermore, the majority of patients in this 
clinic population are private pay patients or commercial health insurance, which provides these 
patients preventive health care resources that would be unavailable to underinsured or uninsured 
patients. The dichotomous distribution of patients in the clinic (Hispanic and Caucasian) may 
have also contributed to findings from the electronic risk screening survey and genetic testing 
results. Many researchers used a more homogenous population of Ashkenazi Jewish people 
when analyzing BRCA gene mutations since there is a much higher than average risk for 
developing breast cancer in this population as stated in the following articles, King et al. (2014), 
Walsh et al. (2017), and Struewing et al. (1997). Further research regarding the influence of 
gender and ethnicity on BRCA1/BRCA2 mutations is needed. 
Limitations 
There were several issues with the electronic tablets during the initial implementation of 
the electronic risk screening survey as previously discussed which may have affected the overall 
screening, testing and referral rates. Out of 329 eligible patients that presented to the clinic 
during the implementation period, only 154 (46.8%) of the patients were asked to complete the 
electronic risk screening survey. Failure to ask the remaining 175 (53.2%) patients most likely 
affected the genetic testing rates and subsequently the ability of the clinic to identify patients 
with BRCA gene mutations. 
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Additional limitations included the one provider who was not as assertive in 
recommending genetic screening as the other provider. Personal bias regarding genetic testing 
influenced both providers participation in the project. This most likely affected the testing rates. 
The number of weeks allotted for this project intervention may have also affected the results, 
since the intervention was not operational as intended until the last week. 
Recommendations 
 The clinic has continued with the intervention of utilizing the electronic tablet screening 
surveys. The nurse practitioner provider informed me that she has continued testing patients and 
following up with a referral to a geneticist counselor. However, the physician provider has 
completely stopped screening all patients for breast cancer using the project implementation 
plan. The nurse practitioner provider verbalized that she would speak with the physician to 
recommend continuing the intervention. With only one provider participating in the project plan, 
approximately 50% of the clinic’s patients that are 18 years and older will be screened. I would 
recommend that the front desk receptionists continue distributing the tablets to patients who are 
18 years and older when they check in to the clinic. This seemed to be the most time efficient 
workflow for the clinic personnel and the patients. I would also recommend the clinic getting 
additional tablets from the genetic testing company in order to help increase the number of 
screenings that can be completed when an electronic tablet experiences loss wi-fi connectivity or 
needs software updates. The nurse practitioner provider of this clinic believes that the number of 
BRCA gene mutations is significant when considering the number of patients participating in the 
project. This has resulted in the nurse practitioner provider continuing the project interventions. 
Perhaps with time and continued implementation of the project the physician provider may 
decide to reinstate the project interventions into his practice.  
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Implications for Practice 
 In 2018, there were no patients identified as being at high risk for breast cancer in this 
clinic's population since no type of breast cancer screening was being implemented. As a result, 
there were also no referrals to genetic counseling in 2018. As of to date since the implementation 
of this project, three (21.4%) patients of the 14 tested have been identified as having a high risk 
of developing breast cancer, and all three women were referred to a geneticist counselor. One of 
these women was confirmed as having a clinically significant BRCA1 gene mutation; another 
one of the women had a mutated gene with unknown clinical significance; and the third women 
was found to have no mutated genes but was still identified as having a very high risk for breast 
cancer due to familial history. Implementation of this project also resulted in informing 101 
(78%) patients that they were at very low risk of developing breast cancer. 
The results of this quality improvement project demonstrate that screening for genetic 
risks aids in identifying those individuals at high risk for developing breast cancer thereby 
encouraging clinicians to develop plans of care that can help minimize these genetic 
predispositions for breast cancer and increase surveillance for breast cancer in these patients. 
Although the project was implemented in a primary care clinic, a similar protocol would be 
suitable for other specialty clinics such as an obstetrics or gynecology clinic since BRCA gene 
mutations also predispose patients to ovarian cancer. Using a modified version of this protocol in 
primary care or urology could also identify men with BRCA genetic mutations that not only 
predispose them to developing breast cancer but also increases their risk of developing prostate 
cancer. Genetic screening protocols could even be implemented in an oncology setting, as it is 
recommended that patients get genetic testing done at time of diagnoses (Childers et al., 2017). 
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There are numerous hereditary genetic screening tools available for screening for breast 
cancer risks. Some that have been recommended by the USPSTF include the Ontario Family 
History Assessment Tool, Manchester Scoring System, Referral Screening Tool, Pedigree 
Assessment Tool and the FHS-7 model (USPSTF, 2018). These screening tools are free for 
providers to use thus providing clinics with a cost-effective method to screen for cancer causing 
genetic mutations. 
Implementation of this project has helped a patient to identify the specific gene that has 
contributed to so many deaths in her family. This has allowed the patient to inform her siblings, 
children, nieces and nephews about the specific gene mutation that runs in their family.  
Knowing what gene mutations a patient has allows for specific testing, which is ultimately less 
expensive, and can bring peace of mind to family members once the genetic mutation is ruled out 
(D’Andrea et al., 2016). More importantly, the patient’s insurance will now cover biannual 
mammograms instead of limiting the patient to an annual mammogram. 
Conclusion 
Healthcare providers have the ability to utilize clinical practice guidelines to potentially 
have a significant impact on their patient populations. Operationalization of a genetic 
screening/testing protocol similar to this one can aid providers in potentially saving lives of 
patients who would otherwise have no idea that they are at high risk for breast cancer. The 
importance of identifying inherited genetic mutations extends beyond the initial treatment period. 
It allows providers to develop treatment plans that include prevention measures that can help 
negate these genetic mutations and increase surveillance of those patients that test positive as 
well as informing other family members of their risk. 
.
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U.S. Preventive Services Task 









The USPSTF recommends that 
primary care providers screen 
women who have family members 
with breast, ovarian, tubal, or 
peritoneal cancer with one of 
several screening tools designed to 
identify a family history that may 
be associated with an increased risk 
for potentially harmful mutations 
in breast cancer susceptibility 
genes (BRCA1 or BRCA2). 
Adequate evidence suggests that 
the overall harms of detection of 
and early intervention for 
potentially harmful BRCA 
mutations are small to moderate. 
 
Implications: The USPSTF 
recognizes that clinical decisions 
involve more considerations than 
evidence alone. Clinicians should 
understand the evidence but 
individualize decision making to 
the specific patient or situation. 
Similarly, the USPSTF notes that 
policy and coverage decisions 
involve considerations in addition 
to the evidence of clinical benefits 
and harms. 
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women who have 
male relatives who 
have a familial 






men and women 
Findings: The study found 
adequate evidence that the overall 
harms of testing, detection, and 
early intervention are small to 
moderate. There was also a 
correlation of genetic mutations in 
descendants of males with a 
familial history of cancer 
particularly those males with 
genetic mutations. 
Implications:  Population-based 
screening of women for BRCA1 
and BRCA2 should become a 




















Henderson, L. M., Hubbard, A.  Purpose: To Design: Quasi- Findings: Women with a history of II III 










R., Sprague, B. L., Zhu,  




between a history 
of a false-positive 
screening 
mammogram result 
and the risk of 
developing breast 
cancer varies 
according to the 
type of 
recommendations 
associated with the 
false-positive 





women ages 40 to 
74 years of age, 
who received a 
mammogram 
between 1994 and 
2009 with a 
sample size of 
12,022,560. 
a false positive screening 
mammogram or who received a 
biopsy recommendation were at 
increased risk of developing breast 
cancer for at least a decade, 
suggesting that prior false positive 
screening results may be useful in 
risk prediction models. 
Implications: The findings suggest 
that false positive mammography 
results should be considered in risk 
prediction models to better stratify 
women into risk categories that 
may be used to personalize breast 
cancer screening and primary 
prevention strategies for individual 
women. 
Puliti, D., Duffy, S. W., 
Miccinesi, G., Koning, H. D., 




estimate rate of 
over diagnosis of 






Sample: 13 studies 
Findings: Determined that false-
positive results are linked with 
higher risk of invasive breast 
cancer later in life. 
 
Implications: Estimation of the 
underlying expected incidence in 
the absence of screening is crucial 
to obtaining reliable estimates of 
over diagnosis. 
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Euler-Chelpin, V. M., Risor, 
M. L., Thorsted, L. B., & 
Vejborg, I. (2012). 
Purpose: Assess 
the risk of 
screened-detected 
breast cancer in 










Findings: Concluded that women 
with false positive results are at 
increased risk for breast cancer.  
Implications:  Advised to actively 
encourage women with false 
positives results for regular breast 
screening as the potential benefit 
from screening is higher than in 
women with false positives than 




Castells, X., Roman, M., 
Romero, A., Blanch, J., 
Zubizarreta, R., Ascunce, N., 





results with the 
cancer detection 
risk in subsequent 
screening 
participations over 
a 17-year period. 
Design: Cohort 
study 
Sample: 762, 506 
women 
 
Findings: False positives showed 
an increased cancer detection risk 
in subsequent screenings. False 
positives involving a cytology or 
biopsy were associated with a 
significantly higher risk of cancer 
detection than false positives 
leading to additional imaging 
procedures 
 
Implications: In the context of 
mammographic screening in which 
large cohorts of women were 
assessed every 2 years, 
personalized risk information could 
be useful to improve the 
effectiveness of breast cancer 
screening by emphasizing the need 
for returning for further screening 
















McCann, J., Stockton, D., & 
Godward, S. (2002). 
Purpose: To 
quantify the 
increased risk with 
increasing anxiety 







whether it extends 
to cancers detected 













Findings: Women experiencing 
false-positive mammographies at 
first screen were less likely to 
return for subsequent screens than 
were non-assessed women, yet 
these women were more likely to 
have increased cancers and larger 
cancers when subsequent interval 
screenings or second screens were 
performed 
 
Implications: A possible 
explanation for the increased risk 
of cancer in women following 
false-positive mammography might 
be the characteristic of women's 
breasts makes it difficult to 
interpret mammographically and 
predisposes these women to the 
risk of a false-positive result which 
in itself is a risk factor for breast 
cancer.  
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Riedl, C. C., Nikolaus, L., 
Bernhart, C., Weber, M., 
Bernathova, M., Tea, M.M,… 
Helbich, H. T. (2015). 
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(MRI) in a high-









Findings: MRI allows early 
detection of familial type breast 
cancer regardless of patient age, 
breast density, or risk status. The 
use of MRI in women with a high 
familial risk for breast cancer has a 
significantly higher sensitivity for 
invasive and preinvasive cancers 
than mammography and 
ultrasound. 
 
Implications: Considering high cost 
and false-positive rates associated 
with the addition of screening 
modalities and considering the high 
sensitivity of MRI alone, the use of 
MRI alone as a screening modality 
in high-risk patients should be 
considered, thus maximizing 
identification of cancers and 





Botkin, R. J., Belmont, W. J., 
Berg, S. J., Berkman, E. J., 
Bombard, Y., Holm, A. I., . . . 
Mclnerney, D. J. (2015). 
Purpose: 
Establishes 






Findings: To date, this limited 
research has not found evidence of 
significant psychosocial harm 
when genetically testing children. 
Implications: Providers should 
offer to explore the reasons why 
parents or adolescents are 
interested in predictive or pre-
dispositional testing for adult-onset 
conditions in children. Providers 
can acknowledge that, in some 
cases, testing might be a reasonable 
decision, but decisions should 




I          VII 










Paluch-Shimon, S., Cardoso, 
F., Sessa, C., Balmana, J., 
Cardoso, M. J., Gilbert, F., & 








Findings: Follow-up counseling 
outlining options for screening for 
early detection, risk-reducing 
measures and issues pertaining to 
fertility in women who have not 
completed becoming pregnant is 
fundamental.  
Implications: If available, genetic 
mutation carriers should be 
encouraged to participate in 
dedicated high-risk follow-up 
clinics that specifically focus on 
follow-up and screening of 
individuals with a known 
hereditary cancer syndrome. 
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evidence on the 
benefits and harms 
of genetic 
counseling and 







Sample: 70 studies 
 
Findings: Genetic counseling 
decreases anxiety and depression 
regarding cancer and improves 
understanding of genetic testing 
results. 
Implications: No trials evaluated 
the effectives of intensive 
screening or risk reducing 
medications in genetic mutation 
carriers, although false positive 
rates, unneeded imaging, and 
unneeded surgeries were higher 
with screening. 
II V 
Armstrong, J., Toscano, M., 
Kotchko, N., Friedman, S., 
Schwartz, M. D., Virgo, K,... 
Sutphen, R. (2015). 
Purpose: To 
identify factors 
associated with use 
of BRCA testing to 
assess whether 











of qualitative and 
descriptive studies 
Sample: 11,159  
Findings: Despite improved patient 
knowledge, understanding, and 
satisfaction among patients who 
receive genetic counseling by a 
genetics clinician, as well as 
multiple guidelines emphasizing 
the importance of genetic 
counseling, most U.S. women 
undergoing BRCA genetic testing 
do not receive this counseling 
service. Lack of physician 
recommendation is the most 
commonly reported reason. 
 
Implications: This finding 
demonstrates the important gaps in 
clinical genetic services. Mandated 
coverage of genetic counseling 
services as a preventive service 
without patient cost sharing should 
contribute to improving clinical 
genetics services and associated 
outcomes in the future. 
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Siriex, J., Fraisse, J., 
Mathoulin-Pelissier, S., 
Leheurteur, M., Vanlemmens, 












Findings: Men who received 
hormonal therapy when compared 
to a matched cohort of women 
showed slightly higher survival 
rates from breast cancer.  
Implications: More biological 
information is needed to improve 
the customized management of 
metastatic breast cancer in men. 
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Cancer Network [NCCN] 
(2019). 




screening in men.   
N/A Clinical 
Practice Guideline. 
Findings: Recommends that men 
age 35 years or older start 
performing self-breast exams and 
have an annual breast exam 
performed by providers. 
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Appendix B: Informed Consent for Hereditary Cancer Genetic Testing 
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Appendix C: BRCA1/BRCA2 Influence on Cancer Types 
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